Drug Profile
NZ 1002
Latest Information Update: 17 Oct 2007
Price :
$50
*
At a glance
- Originator Novazyme Pharmaceuticals
- Class
- Mechanism of Action Iduronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mucopolysaccharidosis I
Most Recent Events
- 04 Feb 2003 No development reported - Preclinical for Mucopolysaccharidosis type I in USA (unspecified route)
- 20 Apr 2001 NZ 1002 has received orphan drug status for Mucopolysaccharidosis type I in USA
- 22 Jan 2001 Preclinical development for Mucopolysaccharidosis type I in USA (Unknown route)